InsiderTrades

Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.

Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-03 · accession 0001628280-25-010672 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-03-05 2025-03-03+ ARWR Anzalone Christopher Richard CEO, Dir M - OptEx $7.75 +300.0K 3.94M +8% +$2.33M
DM 2025-03-05 2025-03-03+ ARWR Anzalone Christopher Richard CEO, Dir S - Sale+OE $17.58 -300.0K 3.77M -7% -$5.27M
DM 2025-03-05 2025-03-03 ARWR Anzalone Christopher Richard CEO, Dir M - OptEx $0.00 -300.0K 185.1K -62% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-04 M A 133,333 $7.75 4,073,802 D — —
2 Common Common Stock 2025-03-03 M A 166,667 $7.75 3,940,469 D — —
3 Common Common Stock 2025-03-03 S D 166,667 $18.03 3,907,135 D — —
4 Common Common Stock 2025-03-04 S D 133,333 $17.02 3,773,802 D — — (F2) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.58 to $ 17.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
5 Derivative Stock Option (right to buy Common Stock) 2025-03-03 M D 133,333 $0.00 51,726 D $7.75 · 2015-03-06 to 2025-03-06 133,333 Common Stock (F3) All options were fully vested and exercisable as of March 6, 2015.
6 Derivative Stock Option (right to buy Common Stock) 2025-03-03 M D 166,667 $0.00 185,059 D $7.75 · 2015-03-06 to 2025-03-06 166,667 Common Stock (F3) All options were fully vested and exercisable as of March 6, 2015.